METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma.

ABSTRACT: Pancreatic carcinogenesis is a complicated and multi-step process. It is substantially assisted by N6-methyladenosine (m⁶A) RNA modification, especially when mutations of driver genes (KRAS, TP53, CDKN2A, and SMAD4) occur. However, the underlying mechanism remains obscure. In this research, we identified m⁶A regulators as potential biomarkers when mutations of driver genes occur, and investigated the role of these m⁶A candidates in pancreatic ductal adenocarcinoma (PDA). We first estimated the abnormal expression patterns of potential m⁶A regulators when all the driver genes are mutated, using The Cancer Genome Atlas and Gene Expression Omnibus databases. METTL16, an m⁶A"writer," was chosen as a unique candidate of PDA, owing to its ma

SUBMITTER: Lu L 

PROVIDER: S-EPMC9500295 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature